Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ClinicalTrials.gov 24,857 recruiting now free trial finder

Find a clinical trial that's recruiting now

Search 24,857 actively recruiting US clinical trials by condition, drug, or state, each entry links straight to its NIH ClinicalTrials.gov record so you can check eligibility and contact the study team.

24,857
trials recruiting now
14%
of all US trials open to enrollment
52
states with recruiting sites

A trial is listed as recruiting when its sponsor has marked it open to new participants on the public registry. Type a condition or drug name (for example, "breast cancer" or "pembrolizumab") to narrow the list, and add a state to find studies with a site near you. Results are ordered with the most relevant recruiting studies first; each card shows the study phase and enrollment target, and opens the full record, including eligibility criteria and contact details, on ClinicalTrials.gov.

100 trials found

Recruiting 150,000 target

Improving Safety and Quality of Tracheal Intubation Practice in Pediatric ICUs

Children's Hospital of Philadelphia

NCT02493478

Recruiting 100,000 target

US National OCS Heart Perfusion (OHP) Registry

TransMedics

NCT05915299

Recruiting 100,000 target

US National OCS Liver Perfusion (OLP) Registry

TransMedics

NCT05940857

Recruiting NA 65,000 target

Transvaginal Ultrasonography as a Screening Method for Ovarian Cancer

John R van Nagell

NCT04473833

Recruiting 40,000 target

Stroke Thrombectomy and Aneurysm Registry

Medical University of South Carolina

NCT04994756

Recruiting NA 18,000 target

School Screening and Telemedicine Specialty Referral to Address Childhood Hearing Loss in Rural Kentucky

University of Arkansas

NCT05513833

Recruiting 10,000 target

Tracking Results of Ablations to Combat AF Registry Generation 2

AtriCure

NCT05111015

Recruiting NA 7,500 target

Prospective Case Collection Study for New Mammography Technologies

Hologic

NCT05199701

Recruiting Phase 4 7,410 target

Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes

VA Office of Research and Development

NCT02915198

Recruiting 7,000 target

Quality of Pediatric Resuscitation in a Multicenter Collaborative

Children's Hospital of Philadelphia

NCT02708134

Recruiting 7,000 target

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

Adela

NCT05366881

Recruiting NA 6,250 target

Platform of Randomized Adaptive Clinical Trials in Critical Illness

University Health Network, Toronto

NCT05440851

Recruiting NA 5,408 target

CSTOP Now! Child Sex Trafficking Stops With You

Ann Coker

NCT05722769

Recruiting Phase 3 5,200 target

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

Colorado Prevention Center

NCT06008197

Recruiting 5,000 target

Montalcino Aortic Consortium: Precision Medicine for Heritable Thoracic Aortic Disease

The University of Texas Health Science Center, Houston

NCT04005976

Recruiting 5,000 target

Multisite Inventory of Neonatal-Perinatal Interventions (MINI) Minimum Dataset

The University of Texas Health Science Center, Houston

NCT05685745

Recruiting 5,000 target

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Duke University

NCT04278404

Recruiting NA 4,000 target

The Fourth Left Atrial Appendage Occlusion Study

Hamilton Health Sciences Corporation

NCT05963698

Recruiting 3,000 target

Gastroparesis Outcome Longitudinal Database Enrolled Numerically

University of Louisville

NCT03876288

Recruiting 3,000 target

Pulmonary Hypertension Association Registry

Pulmonary Hypertension Association

NCT04071327

Recruiting NA 2,800 target

Creating VIP Corps to Reduce Maternal Deaths

Ann Coker

NCT06089109

Recruiting 2,500 target

Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry

Potrero Medical

NCT04669548

Recruiting 2,500 target

MOON Shoulder Instability-Cohort of Patients Undergoing Operative Treatment.

Carolyn M Hettrich

NCT02075775

Recruiting 2,400 target

Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier

Veracyte

NCT06426628

Recruiting NA 2,400 target

Motiva Implants® Post-Approval Study

Motiva USA

NCT06938399

Recruiting NA 2,136 target

Left vs Left Randomized Clinical Trial

Baylor College of Medicine

NCT05650658

Recruiting Phase 3 2,130 target

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

AstraZeneca

NCT07431281

Recruiting NA 2,009 target

LITES Task Order 0005 Prehospital Airway Control Trial (PACT)

Jason Sperry

NCT04100564

Recruiting 2,000 target

Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis

W.L.Gore & Associates

NCT06218875

Recruiting 2,000 target

Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients

Arkansas Children's Hospital Research Institute

NCT05550298

Recruiting 1,800 target

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

Exact Sciences Corporation

NCT06401421

Recruiting NA 1,650 target

Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The PROGRESS Study

Stanford University

NCT05612750

Recruiting Phase 3 1,590 target

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Janssen Research & Development

NCT05552222

Recruiting 1,500 target

Spinal Cord Injury Registry - North American Clinical Trials Network

Robert G. Grossman, MD

NCT00178724

Recruiting 1,500 target

Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain

Boston Scientific Corporation

NCT06827262

Recruiting 1,500 target

Complex Adult Deformity Surgery (CADS)

International Spine Study Group Foundation

NCT04194138

Recruiting Phase 2 1,500 target

Pan Tumor Rollover Study

Bristol-Myers Squibb

NCT03899155

Recruiting NA 1,440 target

Clinical Effectiveness of the "PICU Up!" Multifaceted Early Mobility Intervention for Critically Ill Children

Johns Hopkins University

NCT04989790

Recruiting Phase 3 1,440 target

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Merck Sharp & Dohme

NCT06925737

Recruiting 1,400 target

EXoPERT EMERALD Clinical Study

EXoPERT

NCT07186296

Recruiting Phase 2 1,400 target

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

North American Consortium for Histiocytosis

NCT02205762

Recruiting Phase 1 1,314 target

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Exelixis

NCT05176483

Recruiting Phase 3 1,310 target

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Merck Sharp & Dohme

NCT06136624

Recruiting Phase 3 1,300 target

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age

Vaxcyte

NCT07365826

Recruiting Phase 3 1,300 target

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Kura Oncology

NCT07007312

Recruiting Phase 3 1,300 target

Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)

NYU Langone Health

NCT04474223

Recruiting Phase 2 1,260 target

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

BioNTech SE

NCT06712316

Recruiting NA 1,232 target

Empathic Communication Skills (ECS) Training

Memorial Sloan Kettering Cancer Center

NCT05456841

Recruiting NA 1,205 target

Prevail Global Study

Medtronic Vascular

NCT06535854

Recruiting Phase 3 1,200 target

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Merck Sharp & Dohme

NCT06312176

Recruiting Phase 3 1,200 target

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Merck Sharp & Dohme

NCT06136559

Recruiting NA 1,200 target

The PEERLESS II Study

Inari Medical

NCT06055920

Recruiting Phase 3 1,200 target

Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT

Major Extremity Trauma Research Consortium

NCT04678154

Recruiting NA 1,200 target

Mobile Apps for Preschool Parents (MAPP) Study

Pamela Hull

NCT06520072

Recruiting Phase 3 1,100 target

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

AstraZeneca

NCT07221253

Recruiting Phase 3 1,095 target

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Genmab

NCT06191744

Recruiting 1,065 target

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

Merck Sharp & Dohme

NCT04165798

Recruiting Phase 3 1,046 target

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Merck Sharp & Dohme

NCT06717347

Recruiting NA 1,040 target

Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection

University of Calgary

NCT05219110

Recruiting NA 1,000 target

The Ailliance Post-Market Clinical Study

Medtronic Spinal and Biologics

NCT05856370

Recruiting 1,000 target

Genetic and Environmental Risk Factors for Hemorrhagic Stroke

State University of New York at Buffalo

NCT00682695

Recruiting 1,000 target

Abbott DBS Post-Market Study of Outcomes for Indications Over Time

Abbott Medical Devices

NCT04071847

Recruiting 1,000 target

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

United Therapeutics

NCT06388421

Recruiting 1,000 target

Beat Childhood Cancer Specimen Banking and Data Registry

Giselle Sholler

NCT04715178

Recruiting Phase 3 1,000 target

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Merck Sharp & Dohme

NCT07060807

Recruiting Phase 3 1,000 target

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Bristol-Myers Squibb

NCT06561386

Recruiting 1,000 target

Brain, Blood And Clot or Tissue Registry And Collaboration

Justin Fraser

NCT03153683

Recruiting 1,000 target

International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry

SCAD Alliance

NCT04496687

Recruiting NA 1,000 target

A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD

Cleerly

NCT06713239

Recruiting 1,000 target

Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine

AbbVie

NCT06543914

Recruiting Phase 3 975 target

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

Merck Sharp & Dohme

NCT07216482

Recruiting Phase 2 956 target

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

BicycleTx Limited

NCT06225596

Recruiting 950 target

An Evaluation of Two PTSD Assessments in an Active Duty and Military Veteran Sample

U.S. Army Medical Research and Development Command

NCT04180930

Recruiting Phase 2 901 target

Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Sanofi

NCT05769777

Recruiting 900 target

A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

Ascendis Pharma Endocrinology Division A/S

NCT05820672

Recruiting Phase 3 900 target

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Eli Lilly and Company

NCT07353931

Recruiting Phase 3 895 target

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

AstraZeneca

NCT04862663

Recruiting Phase 3 892 target

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

GlaxoSmithKline

NCT05855200

Recruiting Phase 3 868 target

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

Merck Sharp & Dohme

NCT06077760

Recruiting Phase 3 864 target

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

GlaxoSmithKline

NCT06256588

Recruiting Phase 1 862 target

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

DualityBio

NCT05914116

Recruiting Phase 2 860 target

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Daiichi Sankyo

NCT06161025

Recruiting Phase 3 860 target

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

AstraZeneca

NCT05211895

Recruiting NA 850 target

Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure

Boston Scientific Corporation

NCT07069738

Recruiting NA 850 target

Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure

Abbott Medical Devices

NCT06526195

Recruiting Phase 2 840 target

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

AbbVie

NCT06236438

Recruiting NA 835 target

Health, Environment and Action in Louisville (HEAL) Green Heart Louisville Project

University of Louisville

NCT03670524

Recruiting Phase 3 830 target

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

AstraZeneca

NCT06868277

Recruiting Phase 2 827 target

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

Gilead Sciences

NCT03547973

Recruiting Phase 3 815 target

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

Merck Sharp & Dohme

NCT07218029

Recruiting 800 target

The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors

VastBiome

NCT05037825

Recruiting Phase 2 800 target

Department of Defense PTSD Adaptive Platform Trial - Master Protocol

Global Coalition for Adaptive Research

NCT05422612

Recruiting 796 target

Target Trial Emulation for Pharmacologic Treatment of Neonatal Opioid Withdrawal Syndrome

HELP for NOWS Consortium

NCT07278375

Recruiting Phase 3 795 target

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

Janssen Research & Development

NCT06208150

Recruiting NA 780 target

Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

BrioHealth Solutions

NCT06310031

Recruiting Phase 3 780 target

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

BeiGene

NCT05100862

Recruiting Phase 3 777 target

Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy

SWOG Cancer Research Network

NCT05642611

Recruiting 760 target

Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)

Zimmer Biomet

NCT05787821

Recruiting Phase 3 756 target

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Shanghai Junshi Bioscience Co.

NCT06095583

Recruiting NA 754 target

The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)

Sunnybrook Health Sciences Centre

NCT05427370

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Recruiting status is reported by each study's sponsor and mirrored from the public registry. Always confirm current eligibility and status on ClinicalTrials.gov before contacting a study.

Verify with NIH →